NCT05974410 2025-10-02Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAVM Biotechnology IncAvailable
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available
NCT05612191 2022-11-28Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)Advenchen Laboratories, LLCAvailable